- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.07. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 02.07. | Polyrizon Advances on Test Results | 1 | Baystreet.ca | ||
| 02.07. | Polyrizon: Positive Studiendaten zur Biokompatibilität beflügeln die Aktie | - | Investing.com Deutsch | ||
| 02.07. | Polyrizon completes biocompatibility tests for allergy nasal spray | 1 | Investing.com | ||
| 02.07. | Polyrizon Ltd.: Polyrizon Announces Successful Results for NASARIX Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial | 163 | GlobeNewswire (Europe) | Raanana, Israel, July 02, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal... ► Artikel lesen | |
| 29.06. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 29.06. | Polyrizon erhält Zulassung für klinische Studie zu Allergen-Nasenspray | - | Investing.com Deutsch | ||
| 29.06. | Polyrizon Ltd.: Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial | 220 | GlobeNewswire (Europe) | Raanana, Israel, June 29, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal... ► Artikel lesen | |
| POLYRIZON Aktie jetzt für 0€ handeln | |||||
| 17.06. | Polyrizon receives U.S. patent publication notice for nasal drug delivery platform | 4 | Seeking Alpha | ||
| 17.06. | Polyrizon Ltd.: Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform | 350 | GlobeNewswire (Europe) | Raanana, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal... ► Artikel lesen | |
| 15.06. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 15.06. | Klinische Studie zu Allergieblocker treibt Polyrizon Aktie an | 2 | Investing.com Deutsch | ||
| 15.06. | Polyrizon initiates nasal residence time study for allergy blocker | 2 | Investing.com | ||
| 15.06. | Polyrizon Ltd.: Polyrizon Advances NASARIX Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway | 1 | GlobeNewswire (USA) | ||
| 10.06. | Polyrizon Marches on European Patent | - | Baystreet.ca | ||
| 10.06. | Polyrizon receives European patent application publication | 1 | Investing.com | ||
| 10.06. | Polyrizon Ltd.: Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology | 346 | GlobeNewswire (Europe) | Raanana, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal... ► Artikel lesen | |
| 08.06. | Polyrizon signs two more U.S. sites for allergy trial | 1 | Investing.com | ||
| 08.06. | Polyrizon Ltd.: Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX Trial | 1 | GlobeNewswire (USA) | ||
| 05.06. | Polyrizon verlängert Exklusivitätsfrist für Übernahmegespräche mit Arrow Aviation | 1 | Investing.com Deutsch |
1 2 3 4 5 Weiter >>
82 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,440 | -1,61 % | BERENBERG stuft QIAGEN NV auf 'Hold' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 50 auf 40 Euro gesenkt und die Aktien von "Buy" auf "Hold" abgestuft. Analyst Harry Gillis rechnet mit zunehmendem... ► Artikel lesen | |
| NOVAVAX | 7,050 | +2,03 % | Novavax (NVAX) Registers a Bigger Fall Than the Market: Important Facts to Note | ||
| PALATIN TECHNOLOGIES | 8,620 | +0,23 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| BIOXXMED | 0,830 | -2,35 % | PTA-Adhoc: bioXXmed AG: Kündigung Einbeziehung Freiverkehr | DJ PTA-Adhoc: bioXXmed AG: Kündigung Einbeziehung Freiverkehr
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR Schlagwort(e): Sonstiges
bioXXmed AG: Kündigung Einbeziehung Freiverkehr... ► Artikel lesen | |
| OCUGEN | 1,144 | -3,05 % | Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa | Cumulative sales milestones up to $255 million and modest upfront/near-term development milestonesRoyalties equaling 22% of net salesOcugen to manufacture and supply OCU400 MALVERN, Pa., July 13,... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,960 | +1,00 % | INOVIO Pharmaceuticals, Inc.: Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China | Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate
ApolloBio's... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 4,810 | -1,43 % | COSCIENS Biopharma Inc. Completes Share Capital Amendment | TORONTO, ONTARIO, July 03, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) ("COSCIENS" or the "Company"), today announced the previously announced consolidation (the "Consolidation")... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,327 | +5,14 % | NurExone öffnet mit Exo-Top die Tür zum mexikanischen Exosomenmarkt | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,242 | +4,55 % | PacBio to Report Second Quarter 2026 Financial Results on August 5, 2026 | ||
| REDHILL BIOPHARMA | 0,720 | +2,86 % | RedHill Biopharma Ltd.: RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation | The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
| PHIO PHARMACEUTICALS | 1,130 | +4,63 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors | King of Prussia, Pennsylvania--(Newsfile Corp. - July 21, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,390 | -2,38 % | Onco-Innovations Ltd: Onco-Innovations begins studies to develop ONC010 | ||
| NOVOCURE | 13,960 | -0,11 % | Novocure to Report Second Quarter 2026 Financial Results | Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2026 on July 23, 2026, before the U.S. financial markets open.
Novocure management will host a conference call and webcast... ► Artikel lesen | |
| REVOLUTION MEDICINES | 158,40 | +0,22 % | Revolution Medicines: Nach Bauchspeicheldrüsenkrebs-Durchbruch - geht jetzt alles ganz schnell? | Eine Revolution im wahrsten Sinne des Unternehmensnamens: Die Biotech-Gesellschaft Revolution Medicines kann einen Paradigmenwechsel zur Behandlung von Bauchspeicheldrüsenkrebs einleiten. Die Datenlage... ► Artikel lesen |
Das Unternehmen POLYRIZON LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 13,070 Euro und damit -1,43 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLYRIZON LTD finden Sie auf Wallstreet Online.